The crystal structure of the aldose reductase.NADPH binary complex.Borhani, D.W., Harter, T.M., Petrash, J.M.
(1992) J.Biol.Chem. 267: 24841-24847
- PubMed: 1447221
- PubMed Abstract:
- Kinetic Alteration of Human Aldose Reductase by Mutagenesis of Cysteine Residues
Petrash, J.M.,Harter, T.,Tarle, I.,Borhani, D.
(1993) Adv.Exp.Med.Biol. 328: 289
- Probing the Active Site of Aldose Reductase: Site-Directed Mutagenesis of Asp-43, Tyr-48, Lys-77, and His-110
Tarle, I.,Borhani, D.W.,Wilson, D.K.,Quiocho, F.A.,Petrash, J.M.
() TO BE PUBLISHED --: --
- Involvement of Cysteine Residues in Catalysis and Inhibition of Human Aldose Reductase: Site Directed Mutagenesis of Cys-80,-298 and-303
Petrash, J.M.,Harter, T.M.,Devine, C.S.,Olins, P.O.,Bhatnagar, A.,Liu, S.,Srivastava, S.K.
(1992) J.Biol.Chem. 267: 24833
- Studies on Pig Aldose Reductase: Identification of an Essential Arginine in the Primary and Tertiary Structure of the Enzyme
Kubiseski, T.J.,Green, N.C.,Borhani, D.W.,Flynn, T.G.
() TO BE PUBLISHED --: --
Aldose reductase is an NADPH-dependent oxidoreductase that catalyzes the reduction of a broad range of aldehydes, including glucose. Since aldose reductase has been strongly implicated in the development of the chronic complications of diabetes melli ...
Aldose reductase is an NADPH-dependent oxidoreductase that catalyzes the reduction of a broad range of aldehydes, including glucose. Since aldose reductase has been strongly implicated in the development of the chronic complications of diabetes mellitus, much effort has been devoted to understanding the structure and mechanism of this enzyme, and many aldose reductase inhibitors have been developed as potential drugs for the treatment of these complications. We describe here the 2.75 A crystal structure of recombinant human aldose reductase (Cys-298 to Ser mutant) complexed with NADPH. This mutant displays unusual kinetic behavior characterized by high Km/high Vmax substrate kinetics and reduced sensitivity to certain aldose reductase inhibitors. The crystal structure revealed that the enzyme is a beta/alpha-barrel with the coenzyme-binding domain located at the carboxyl-terminal end of the parallel strands of the barrel. The enzyme undergoes a large conformational change upon binding NADPH which involves the reorientation of loop 7 to a position which appears to lock the coenzyme into place. NADPH is bound to aldose reductase in an unusual manner, more similar to FAD- rather than NAD(P)-dependent oxidoreductases. No disulfide bridges were observed in the crystal structure.
BioCryst Pharmaceuticals, Inc., Birmingham, Alabama 35244.